Physicochemical Characterisation And Dissolution Properties Of Spironolactone Solid Binary Systems
DOI:
https://doi.org/10.22270/ajprd.v12i4.1444Abstract
Objective: To study the physicochemical characterisation and dissolution properties of Spironolactone complexing it with β-Cyclodextrin and Hydroxypropyl-β-Cyclodextrin in different molar ratios (1:1 M and 1:2 M).
Design Interventions: Spironolactone belonging to BCS class II, exhibits low and variable oral bioavailability due to its poor aqueous solubility. Enhancement in solubility and dissolution rate leads to an increase in its oral bioavailability. Solid binary systems were prepared by Physical mixture, Kneading method, Microwave irradiation and Freeze-drying method. They were evaluated by in vitro dissolution studies and characterised using different analytical techniques.
Main Outcome Measures: The host guest interactions studied by different techniques confirmed true inclusion of Spironolactone with β-Cyclodextrin and Hydroxypropyl-β-Cyclodextrin at 1:1 M and 1:2 M.
Results: Overall, the rank order of improvement in dissolution properties of Spironolactone with ratios is 1:2 M > 1:1 M, methods Freeze-drying > Microwave irradiation > Kneading method > Physical mixture and complexing agent Hydroxypropyl-β-Cyclodextrin > β-Cyclodextrin.
Conclusion: Among the developed Spironolactone SBSs, the SBS prepared with HP- βCD of 1:2 M ratio by Freeze drying method showed good result in dissolution study which shows the maximum release of drug in the range of 95.6%.
Downloads
References
Lipinski CA et al. Poor aqueous solubility: an industry wide problem in drug discovery.American Pharm Rev, 2002; 5:82-85.
Patel MM, Patel DM.Fast dissolving Valdecoxib tablets containing solid dispersion of Valdecoxib.Indian J Pharm Sci2006; 68(2):222-226.
Searle.Aldactone (Spironolactone) tablets prescribing information, Chicago 2003.
Sica, Domenic A.Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis.Heart Failure Reviews2005;10(1):23-29.
Maron BA, Leopold JA. Mineralocorticoid receptor antagonists and endothelial function. CurrOpinInvestig Drugs 2008; 9(9):963–969.
Friedman and Adam J. Spironolactone for adult female acne. Cutis2015;96(4): 216-17.
Sanjoy KD, Rajan R, Sheba D, et al.Cyclodextrins- The molecular container. Res J Pharm BiolChemSci 2013; 4(2):0975- 8585.
Hong HL, Sun JF, Ying Z, et al.Preparation and Evaluation of TosufloxacinTosylate inclusion complex.Indian J Pharm Sci 2019; 81(2): 249- 58.
Melita H, Majda S, Mirsada S, et al. Inclusion complex of Fexofenadine Hydrochloride with cyclodextrins.Med J Chem 2021; 11(3):282-89.
Adel FA, Gamal MM, Diaa EZ, et al. Preparation, characterization, dissolution, and permeation of Flibanserin 2-HP-b-cyclodextrin inclusion complexes. Saudi Pharm J 2021; 29(9):963-975.
Dounia S, Milad B, Zineb E, et al. Solubility enhancement of Mefenamic acid by inclusion complex with β-cyclodextrin: in silico modelling, formulation, characterisation and in vitro studies.JEnzy Inhibition and Med Chem 2021; 36(1):605-17.
Bedriye T, Damla CA, Menemşe G. Melatonin/HPβCD complex: Microwave synthesis, integration with chitosan scaffolds and inhibitory effects on MG-63CELL. Int J Pharmaceutics 2015; 496:801-11.
Sultan A, Syed SI, Afzal H et al. Potential of solid dispersions to enhance solubility, bioavailability, and therapeutic efficacy of poorly water-soluble drugs: newer formulation techniques, current marketed scenario and patents.Drug Del 2020; 27(1):1625-43.
FarhatjahanIS,Meenakshi BP, Naazneen IS et al. Preparation and Characterization of Lercanidipine Hydrochloride Inclusion complex with β-cyclodextrin and effect of complexation on solubility and dissolution. Res J Pharm and Tech 2017; 10(4):951-58.
Samuel S, Javed I, Ahmad BA. Insights into the ameliorating ability of mesoporous silica in modulating drug release in ternary amorphous solid dispersion prepared by hot melt extrusion. Eur J Pharm and Biopharm2021; 165:244–58.
Vinod TW, Ritu MG, Rajendra DW. Solid Dispersion (Kneading) Technique: A Platform for Enhancement Dissolution Rate of Valsartan Poorly Water-soluble Drug.Int J Pharm QA 2020;11(1):20-24.
Bharati A, Anand KY, Mallikarjuna SC. Characterization of solid binary systems of Efavirenz and Hydroxypropyl-β-Cyclodextrin.Int J Res Dev Pharm Life Sci 2019; 8(1):15-20.
Shuang G, Chao B, Qiuyu J, et al.Preparation and characterization of Cyanazine– Hydroxypropyl-βeta-cyclodextrin inclusion complex. RSC Adv 2019; 45(9):26109–115.
Rumondor AC, Marsac PJ, Stanford LA and Taylor LS. Phase behavior of poly vinyl pyrrolidone containing amorphous solid dispersions in the presence of moisture. Mol Pharm2009;6(5):1492– 1505.
Published
Versions
- 2024-08-23 (2)
- 2024-08-15 (1)
How to Cite
Issue
Section
Copyright (c) 2024 Bharati Arali , Pruthvi Devaraj, Uma A Patil, A Madhu
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.